SCHEMBL30218779

SCHEMBL30218779

O=c1[nH]c(=O)n(-c2ccccn2)c(=O)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
GAA P10253 2/20 0.45
MAPK1 P28482 2/20 0.45
EP300 Q09472 1/20 0.44
KAT2B Q92831 1/20 0.44
BTK Q06187 2/20 0.44
CRBN Q96SW2 1/20 0.44
CHEK1 O14757 1/20 0.44
AURKA O14965 1/20 0.44
DAPK3 O43293 1/20 0.44
JAK2 O60674 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
PAK4 O96013 1/20 0.44
ABL1 P00519 1/20 0.44
NTRK1 P04629 1/20 0.44
FYN P06241 1/20 0.44
CSF1R P07333 1/20 0.44
RET P07949 1/20 0.44
IGF1R P08069 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30423157 0.79 GABRP (0.53) GAAMAPK1AURKACDK5KDM4E
SCHEMBL4161172 0.79 GABRP (0.53) GAAMAPK1AURKACDK5KDM4E
SCHEMBL13933686 0.78 DAO (0.57) SMN1; SMN2GAAMAPK1AURKAPRKCQ
SCHEMBL11436500 0.78 DAO (0.57) SMN1; SMN2GAAMAPK1EP300KAT2B
SCHEMBL28379997 0.77 SMN1; SMN2 (0.55) SMN1; SMN2GAAMAPK1EP300KAT2B
SCHEMBL6975916 0.76 NPEPPS (0.54) SMN1; SMN2GAAMAPK1ALDH1A1KDM4E
SCHEMBL8331276 0.74 KDM4E (0.48) SMN1; SMN2GAAALOX5NOX4NOX1
SCHEMBL12661008 0.74 EP300 (0.53) SMN1; SMN2GAAMAPK1EP300KAT2B
SCHEMBL26646440 0.73 ADORA2B (0.51) SMN1; SMN2GAAMAPK1ALDH1A1
SCHEMBL30681658 0.73 SMN1; SMN2 (0.43) SMN1; SMN2GAAMAPK1EP300KAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP claimed